(Q37180708)

18 August 2017

Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy (English)

1 reference

18 August 2017

1 reference

1 reference

7

I L Andrulis

1 reference

18 August 2017

F P O'Malley

1

1 reference

18 August 2017

S Chia

2

1 reference

18 August 2017

D Tu

3

1 reference

18 August 2017

L E Shepherd

4

1 reference

18 August 2017

M N Levine

5

1 reference

18 August 2017

V H Bramwell

6

1 reference

18 August 2017

K I Pritchard

8

1 reference

18 August 2017

language of work or name

English

0 references

publication date

28 April 2009

1 reference

Journal of the National Cancer Institute

18 August 2017

1 reference

18 August 2017

101

1 reference

18 August 2017

9

1 reference

18 August 2017

644-650

1 reference

HER-2 and topoisomerase II as predictors of response to chemotherapy

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677575

HER2/neu in systemic therapy for women with breast cancer: a systematic review

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677575

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677575

Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677575

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677575

retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677575

Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Gr

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677575

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677575

HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677575

Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2677575

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

3 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19401546

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19401546

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19401546

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/JNCI/DJP067

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

19401546

1 reference